Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors thank the patients who participated in this study, and their supportive families, as well as the investigators, sub-investigators, and coordinators at each of the study sites. The study was supported by Pharmacyclics LLC, an AbbVie Company (Sunnyvale, CA, USA). Editorial support was provided by Emily Chastain, PhD, and was funded by Pharmacyclics LLC, an AbbVie Company.

Disclosures statement

JW: consultancy/advisory role with AbbVie, Arqule, AstraZeneca, BeiGene, Janssen, and Pharmacyclics LLC, an AbbVie Company; research funding from AbbVie, Karyopharm, Loxo Oncology, Morphosys, and Verastem; AT: honoraria from and speakers’ bureau for AbbVie, AstraZeneca, BeiGene, and Janssen; TM: honoraria from AbbVie, AstraZeneca, Gilead, Janssen, and Novartis; consultancy/advisory role with Morphosys and Sunesis; travel expenses from AbbVie, Gilead, and Janssen; TS: consultancy/advisory role with AstraZeneca, BeiGene, Celgene, Juno Therapeutics, and Kite Pharma; research funding to institution from AstraZeneca, BeiGene, Celgene, Juno Therapeutics, Kite Pharma, Oncternal, Pharmacyclics LLC, an AbbVie Company, and TG Therapeutics; speakers' bureau for AstraZeneca, Janssen, and Pharmacyclics LLC, an AbbVie Company; PH: consultancy/advisory role with AbbVie, AstraZeneca, and Janssen; research funding from AbbVie, AstraZeneca, Gilead, Janssen, Novartis/GSK, Pharmacyclics LLC, an AbbVie Company, and Roche; speakers’ bureau for AbbVie AstraZeneca, Janssen, and Roche; travel expenses from AbbVie and Janssen; JCB: stock ownership in Vincerx; consultancy/advisory role with AstraZeneca, Janssen, Kura, Novartis, and Syndax; research funding from Pharmacyclics LLC, an AbbVie Company, and Zencor; patents, royalties, or other intellectual property with The Ohio State University; travel expenses from Gilead, Janssen, Novartis, Pharmacyclics LLC, an AbbVie Company, and TG Therapeutics; PG: honoraria from and consultancy/advisory role with AbbVie, Acerta/AstraZeneca, Adaptive, ArQule/MSD, BeiGene, Celgene/Juno Therapeutics/BMS, Gilead, Janssen, Lilly/Loxo, and Roche; research funding from AbbVie, AstraZeneca, Gilead, Janssen, Novartis, and Sunesis; SPM: honoraria from and speakers’ bureau for AbbVie, AstraZeneca, and Janssen; SD: employment with Pharmacyclics LLC, an AbbVie Company, and Horizon Therapeutics; stock ownership in AbbVie, Bristol Myers Squibb, Exelixis, Gilead, GlaxoSmithKline, Horizon Therapeutics, Myovant Sciences, and Revance Therapeutics; CIA: employment with Pharmacyclics LLC, an AbbVie Company, and Eisai Inc.; stock ownership in AbbVie; JPD: employment with Pharmacyclics LLC, an AbbVie Company; stock ownership in AbbVie; SMO: consultancy/advisory role with AbbVie, Alexion, Amgen, Aptose Biosciences Inc., Astellas, Autolus, Bristol Myers Squibb, Celgene, Eisai, Gilead, GlaxoSmithKline, Janssen Oncology, Johnson and Johnson, Juno Therapeutics, Merck, NOVA Research Company, Pfizer, Pharmacyclics LLC, an AbbVie Company, Sunesis, TG Therapeutics, Vaniam Group LLC, Verastem, and Vida Ventures; research funding from Acerta, Caribou, Gilead, Kite, Pfizer, Pharmacyclics LLC, an AbbVie Company, Regeneron, Sunesis, and TG Therapeutics; PMB: consultancy/advisory role with AbbVie, AstraZeneca, Celgene, Genentech, Gilead, Janssen, Merck, Morphosys, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics, and TG Therapeutics.

Data availability statement

Requests for access to individual participant data from clinical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.

Additional information

Funding

The study was sponsored by Pharmacyclics LLC, an AbbVie Company, and was designed by the sponsor in collaboration with investigators of the Steering Committee. Janssen Research and Development provided funding for the study and was permitted a courtesy review of the manuscript. Data were collected by the investigators and their research teams. The sponsor confirmed accuracy of the data and compiled them for analysis.